Annuncio • May 21
IXICO plc Reaffirms Earnings Guidance for the Full Year 2026 IXICO plc reaffirmed earnings guidance for the full year 2026. For the year, the company remains focused on delivering on guidance of 15% revenue growth. Annuncio • May 13
IXICO Plc Releases Latest Version Of AI-Driven Neuroimaging Technology Platform IXICO plc announced the latest version (v.10) of IXI™, IXICO's proprietary AI enabled neuroimaging platform that delivers clinical trial imaging and biomarker insights in neurological disease research. The IXI™ 10.0 release brings advances in image reading precision and analysis, enables larger and faster image data processing, and integrates new tools for remote image access and data quality qualification. The latest generation of IXI™ lays the foundation for IXICO's technology to move beyond its traditional iCRO remit as part of the Group's TechBio strategy. The strategy is focused on increasing IXICO's addressable market by enabling external organizations to directly access IXICO's technology via licensing, technology integration and partnering models such as the recently announced collaboration with Medidata (26 March 2026). Designed by neuroscience and data science experts, the IXI™ Platform is a proprietary suit of technologies and AI tools tailor-made for neurological disease complexity. IXI™ uses machine learning and deep learning to reliably process data from global trials and build algorithms that precisely measure key imaging biomarkers associated with the identification, progression and treatment of Alzheimer's, Parkinson's, Huntington's and other rare neurological diseases. It is the only technology platform of its kind specifically built for, and exclusively focussed on, neuroimaging processing and neurological biomarker analysis. IXI™ is being used every day across the world. With over 30 cutting edge analytics algorithms the Platform integrates standardised high quality image data capture, image reading, advanced analysis and regulatorily compliant reporting of clinical data. IXI™ supports the biopharma industry to develop new medicines and diagnostic measures, informing decisions earlier in the drug development process via a single end to end platform. Annuncio • Apr 22
Ixico plc Provides Earnings Guidance for the First Half Ended 31 March 2026 Ixico plc provided earnings guidance for the first half ended 31 March 2026. For the period, Revenues expected to be up 23% to £3.9 million (First half of 2025: £3.2m), driven by new contract wins, contract extensions and an increased volume of analyses in first half of 2026 relative to the equivalent prior period. Annuncio • Apr 21
IXICO plc to Report First Half, 2026 Results on May 19, 2026 IXICO plc announced that they will report first half, 2026 results on May 19, 2026 Annuncio • Apr 08
IXICO plc has completed a Follow-on Equity Offering in the amount of £0.03032 million. IXICO plc has completed a Follow-on Equity Offering in the amount of £0.03032 million.
Security Name: Ordinary shares
Security Type: Common Stock
Securities Offered: 379,000
Price\Range: £0.08
Transaction Features: Regulation S Annuncio • Feb 26
IXICO plc Presents Automated Capabilities to Measure Brain Volume Loss on Magnetic Resonance Imaging (MRI) Within its IXI Platform IXICO plc announced it has presented new demonstrating that automated capabilities to measure brain volume loss on magnetic resonance imaging (MRI) within its IXI Platform are at a minimum matching, and in some measures exceeding, the performance of semi-manual methods which require manual analysis by (human) experts. The accurate measurement of brain volume shrinkage (brain atrophy), caused by the loss of brain cells and the breakdown of connections between them, is fundamental to developing new treatments for a number of neurodegenerative diseases, including Huntington's Disease (HD). Traditionally, researchers have relied on a semi-manual approach to measure brain volume loss, known as the Boundary Shift Integral (BSI) which is currently considered to be the 'gold standard' method of analysis. In a recent study conducted by IXICO and a large US pharmaceutical partner, the results show that automated capabilities to measure brain atrophy on MRI within its IXI Platform match or exceed the performance of the semi-manual BSI method, providing an advanced, cost-effective and scalable solution to support clinical trials in HD. Of the three approaches evaluated to measure brain atrophy, IXICO demonstrated it was the most sensitive method for detecting whole brain and caudate (a small region deep in the brain impacted early in HD) volume loss. Annuncio • Feb 06
IXICO plc Appoints Tanya Voloshen as Chief Commercial Officer IXICO plc announced that it has appointed Tanya Voloshen as Chief Commercial Officer (CCO) based in Boston, Massachusetts (USA). Tanya joins IXICO from Perceptive Inc., a global contract research organisation (CRO) where she held the role as SVP Commercial. Prior to joining Perceptive, Tanya held senior commercial leadership roles for international clinical trial and medical technology companies with a focus on neuroscience and medical imaging including Clario (now part of Thermo Fisher Scientific), QMENTA and ConcertAI. Tanya started her career in the pharmaceutical industry working for Johnson & Johnson and Sanofi. Annuncio • Dec 09
IXICO plc, Annual General Meeting, Jan 23, 2026 IXICO plc, Annual General Meeting, Jan 23, 2026. Location: cct venues smithfield, two east poultry avenue, smithfield, ec1a 9pt, london United Kingdom Annuncio • Dec 01
IXICO plc Announces Scientific Advisory Board Appointments, Effective December 1, 2025 IXICO plc announced at the CTAD conference held on December 1, 2025, that it has appointed two leading global experts in the field of Alzheimer's Disease (AD) and cerebrovascular disease (CVD) as advisors to the Company. Professor Michael Weiner, and Professor Joanna Wardlaw join IXICO's advisory board with immediate Effective December 1, 2025. Michael Weiner, MD, is a Professor Emeritus in Radiology and Biomedical Imaging, Medicine, Psychiatry, and Neurology at the University of California, San Francisco. He is Principal Investigator of the Alzheimer's Disease Neuroimaging Initiative, which is the largest observational study in the world concerning Alzheimer's Disease. He is the former Director of the Center for Imaging of Neurodegenerative Diseases (CIND) at the San Francisco Veterans Affairs Medical Center. His overall research goals are to participate in the development of effective treatments and methods for early detection of Alzheimer's disease and other brain disorders. Recently he has focused on developing voice agents for assessments in AD clinical trials. Michael is the Principal Investigator of the Alzheimer's Disease Neuroimaging Initiative, a 19-year national longitudinal study of over 3,500 subjects which is aimed at validating biomarkers for Alzheimer's disease at 63 sites across the USA and Canada for cognitive testing, MRI, PET, and lumbar puncture. He also launched the BrainHealthRegistry.org which is an internet-based registry with the overall goal of accelerating development of effective treatments for brain diseases. This website registry recruits, screens, and longitudinally monitors brain function on more than 100,000 participants. Dr. Weiner has mentored over 200 postdoctoral fellows, has authored over 1000 peer reviewed research papers and 71 book chapters. Joanna is ais Professor of Applied Neuroimaging at the University of Edinburgh, Foundation Chair of the UK DRI at Edinburgh, Director of the Row Fogo Centre for research into Ageing and the Brain, and Consultant Neuroradiologist for NHS Lothian. Her work focuses on understanding the brain and its blood supply, and treatments to improve blood flow to the brain, including thrombolytic drugs that are now in routine use to treat stroke, and more recently treatments for small vessel disease and vascular dementia. Working with many colleagues, she has been instrumental in advancing understanding of the causes of cerebral small vessel disease and is now testing treatments in clinical trials. She has set up national research imaging facilities, co-ordinated international research networks, advanced stroke care worldwide and published over 1000 papers. A Fellow of the Royal Society of Edinburgh and the UK Academy of Medical Sciences, she has received awards from many UK and international brain and heart organizations and was made a Commander of the Order of the British Empire (CBE) for services to Medicine and Neuroscience in 2016. Annuncio • Nov 27
IXICO plc to Report Fiscal Year 2025 Results on Dec 09, 2025 IXICO plc announced that they will report fiscal year 2025 results on Dec 09, 2025 Annuncio • Jun 10
IXICO plc Announces FDA Clearance of New Alzheimer's Disease Blood Based Diagnostic Biomarker IXICO plc outlined its role in the validation of a new Alzheimer's Disease (AD) diagnostic biomarker for client Fujirebio Diagnostics Inc. ("Fujirebio"), a global leader in the field of high-quality in vitro diagnostic (IVD) testing. The imaging analysis, conducted via IXICO's AI-driven platform, has supported Fujirebio's 510(k) FDA clearance for a new blood-based test that will help advance diagnosis and drug development in AD. The analysis included datasets from the Global Alzheimer's Platform Foundation's Bio-Hermes-001 study, of which both Fujirebio and IXICO are partners. As Bio-Hermes' imaging partner, IXICO led the standardisation, collection and expert analysis of PET data which served as the gold standard assessment of amyloid pathology in Fujirebio's FDA filing. On 16 May Fujirebio announced that it received clearance for its Lumipulse®? G pTau 217/b-Amyloid 1-42 Plasma Ratio in-vitro diagnostic (IVD) test for the assessment of amyloid pathology In adult patients, aged 50 or older, being evaluated for Alzheimer's disease and other causes of cognitive decline. The test, which was granted Breakthrough Device Designation by the FDA, is the first FDA cleared blood-based IVD test in the U.S. to aid the identification of patients with amyloid pathology associated with AD. Fujirebio's FDA clearance is based on data from a multi-center clinical study of 499 individuals in which amyloid positivity derived from the Lumipulse G pTau217/ss-Amyloid 1- 42 Plasma Ratio has been shown to be sufficiently comparable with results obtained through amyloid PET scan or CSF tests. These findings indicate that the new blood test can reliably predict the presence or absence of amyloid pathology associated with Alzheimer's disease at the time of the test in patients who are cognitively impaired. The test is intended for patients presenting at a specialized care setting with signs and symptoms of cognitive decline. The results must be interpreted in conjunction with other patient clinical information. The analysis by IXICO corresponds to the announcement made by the Company on 27 February 2025 that it had won a contract with an, at the time, undisclosed multinational biotechnology company. IXICO is now able to confirm that this company was Fujirebio. The imaging element of the clinical trial conducted on behalf of Fujirebio marks an expansion in IXICO's neuroimaging biomarker analyses capabilities beyond therapeutic clinical trial assessment to the analysis and validation of clinical diagnostic biomarkers. Annuncio • Dec 05
IXICO plc, Annual General Meeting, Jan 24, 2025 IXICO plc, Annual General Meeting, Jan 24, 2025. Location: ixicos office, 4th floor griffin court, 15 long lane, ec1a 9pn, london United Kingdom Annuncio • Nov 25
IXICO plc to Report Fiscal Year 2024 Results on Dec 04, 2024 IXICO plc announced that they will report fiscal year 2024 results on Dec 04, 2024 New Risk • Nov 14
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Shareholders have been substantially diluted in the past year (92% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable next year (UK£2.0m net loss next year). Market cap is less than US$100m (€9.76m market cap, or US$10.3m). New Risk • Oct 11
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 55% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (55% increase in shares outstanding). Market cap is less than US$10m (€8.26m market cap, or US$9.03m). Minor Risks Currently unprofitable and not forecast to become profitable next year (UK£2.0m net loss next year). Share price has been volatile over the past 3 months (9.4% average weekly change). Annuncio • Aug 14
Ixico plc Provides Revenue Guidance for the Year Ending 30 September 2024 Ixico plc provided revenue guidance for the year ending 30 September 2024. For the period, revenue is expected to be between £5.5 million and £5.9 million (2023: £6.7 million) reflecting growth of at least 20% in revenues across the second half of the year as compared to the first half (H1 2024: £2.5 million). Annuncio • Aug 05
IXICO plc Appoints Bram Goorden as Chief Executive Officer, Effective 19 August 2024 IXICO plc announced that Bram Goorden will be appointed as Chief Executive Officer of the Company from 19 August 2024. Bram has over 20 years of leadership experience in BioPharma and precision medicine, serving in roles where he has been instrumental in shaping commercial strategies for scale, growing revenues and ultimately enabling the realisation of shareholder value. He has strong CNS experience, and established networks within IXICO's target market bringing sector relevant strength to IXICO. Bram joins having recently held C-level roles at Eagle Genomics Limited where he drove key industry alliances for their AI platform and NASDAQ listed SOPHiA Genetics Inc. where he expanded their US footprint and delivered key alliances with Pharma. In previous roles as VP International Business, he expanded Foundation Medicine Inc.'s global presence in precision medicine including programs with major BioPharma partners, and as division CEO of US-based Prometheus Laboratories he delivered shareholder value via the integration of the company into Nestle Health Science SA. Bram has also held senior management positions within UCB Pharma SA and Eli Lilly & Co, both in the field of CNS medicine. Bram's neuroscience experience is demonstrated at Board level through current and past roles at Mantis Photonics AB and Cerecin Inc. Bram started his career as a management consultant at Accenture. Bram's appointment follows the announcement made on 12 January 2024, of Giulio Cerroni's intention to retire from his role as CEO by the end of 2024. Giulio will step down as a director of the Company on 16 August 2024. Giulio continues to be available to the Company to support an orderly hand over. New Risk • May 21
New major risk - Revenue and earnings growth Earnings have declined by 14% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 14% per year over the past 5 years. Market cap is less than US$10m (€4.03m market cap, or US$4.38m). Minor Risk Share price has been volatile over the past 3 months (8.0% average weekly change). Annuncio • May 08
IXICO plc to Report First Half, 2024 Results on May 21, 2024 IXICO plc announced that they will report first half, 2024 results on May 21, 2024 Annuncio • Jan 13
Giulio Cerroni to Retire as CEO of IXICO plc, Effective End of 2024 IXICO plc announced that Giulio Cerroni has informed the Board of his intention to retire from his role as Chief Executive Officer ("CEO") of the Company by the end of 2024 in accordance with his notice period and to ensure a smooth handover of responsibilities. The Board has begun the process to appoint a new CEO in line with its succession plan and will update the market in due course. Annuncio • Jan 12
Giulio Cerroni to Retire as Director of IXICO plc, Effective End of 2024 IXICO plc announced that Giulio Cerroni has informed the Board of his intention to retire from his role as director of the Company by the end of 2024 in accordance with his notice period and to ensure a smooth handover of responsibilities. Reported Earnings • Dec 06
Full year 2023 earnings released: UK£0.024 loss per share (vs UK£0.021 profit in FY 2022) Full year 2023 results: UK£0.024 loss per share (down from UK£0.021 profit in FY 2022). Revenue: UK£6.67m (down 23% from FY 2022). Net loss: UK£1.18m (down 214% from profit in FY 2022). Revenue is forecast to grow 4.0% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has only fallen by 48% per year, which means it has not declined as severely as earnings. Annuncio • Dec 05
IXICO plc, Annual General Meeting, Jan 25, 2024 IXICO plc, Annual General Meeting, Jan 25, 2024, at 10:30 Coordinated Universal Time. Location: CCT Venues Smithfield, Two East Poultry Avenue, Smithfield, London United Kingdom Annuncio • Nov 27
IXICO plc to Report Fiscal Year 2023 Results on Dec 05, 2023 IXICO plc announced that they will report fiscal year 2023 results on Dec 05, 2023 New Risk • Oct 13
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: €9.08m (US$9.54m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 41% per year for the foreseeable future. Market cap is less than US$10m (€9.08m market cap, or US$9.54m). Minor Risk Profit margins are more than 30% lower than last year (1.8% net profit margin). Annuncio • Oct 06
Ixico plc Appoints Dipti Amin as an Independent Non-Executive Director and the Remuneration and Audit Committees IXICO plc announced the appointment of Dr. Dipti Amin as an Independent Non-Executive Director of the Company with immediate effect. Dr. Amin is an experienced non-executive director and medically trained senior executive with extensive commercial, leadership and operational experience, in medicine, pharmacology and the highly regulated healthcare and research sectors. Dr. Amin spent over twenty years of her executive career at IQVIA, occupying senior positions in compliance, drug safety and medical affairs and will bring significant additional pharmaceutical and CRO experience to the Company. Dr. Amin currently sits on the Boards of the University of Hertfordshire and Lineage Cell Therapeutics, a US based biotechnology company, having previously sat on the Boards of companies in both the private and public sectors. Dr. Amin will also be joining the Remuneration and Audit committees with immediate effect. New Risk • Sep 29
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 41% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 41% per year for the foreseeable future. Minor Risks Profit margins are more than 30% lower than last year (1.8% net profit margin). Market cap is less than US$100m (€10.6m market cap, or US$11.2m). Annuncio • Sep 29
IXICO plc Provides Earnings Guidance for the Full Year of 2023 IXICO plc provided earnings guidance for the full year of 2023. For the year, the company expects revenue to be £6.5 million (2022: £8.6 million). This reduction on the prior period principally reflects the final year of impact of the previously announced early cessation of large client trials coupled with some delays in new client trial initiations. Reported Earnings • May 24
First half 2023 earnings released: UK£0.015 loss per share (vs UK£0.004 profit in 1H 2022) First half 2023 results: UK£0.015 loss per share (down from UK£0.004 profit in 1H 2022). Revenue: UK£3.20m (down 18% from 1H 2022). Net loss: UK£725.0k (down 436% from profit in 1H 2022). Revenue is forecast to stay flat during the next 2 years compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has fallen by 36% per year, which means it is performing significantly worse than earnings. Annuncio • May 11
IXICO plc to Report First Half, 2023 Results on May 23, 2023 IXICO plc announced that they will report first half, 2023 results on May 23, 2023 Annuncio • May 10
IXICO plc Provides Earnings Guidance for Six Months to 31 March 2023 and Full Year of 2024 IXICO plc provided earnings guidance for six months to 31 March 2023 and full year of 2024. for the period, revenues expected to be £3.2 million for six months to 31 March 2023 (H1 2022: £3.9 million); Loss before interest, tax, depreciation, and amortisation to 31 March 2023 expected to be £0.6 million (H1 2022: £0.5 million profit).The Board reaffirmed market guidance for the full year and return to revenue growth in 2024. Annuncio • Feb 07
IXICO plc Provides Revenue Guidance for the Year Ending September 30, 2024 IXICO plc provided revenue guidance for the year ending September 30, 2024. For the year, the company expects to achieve double digit revenue growth in the year to 30 September 2024. The Company has diversified its orderbook and the Board expects to see revenue growth in 2024 as it continues to build upon the contract and client wins of the last two years. This return to revenue growth will be a key step on the path back to profitability. Reported Earnings • Dec 08
Full year 2022 earnings released: EPS: UK£0.021 (vs UK£0.033 in FY 2021) Full year 2022 results: EPS: UK£0.021 (down from UK£0.033 in FY 2021). Revenue: UK£8.64m (down 6.0% from FY 2021). Net income: UK£1.03m (down 35% from FY 2021). Profit margin: 12% (down from 17% in FY 2021). Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Senior Independent Director Mark Warne was the last independent director to join the board, commencing their role in 2016. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Annuncio • Sep 01
IXICO plc Provides Revenue Guidance for the Financial Year 2023 IXICO plc provided revenue guidance for the financial year 2023. For the period, the company expects revenues of approximately £7 million, of which over £5 million is already contracted. This guidance reflects the impact of the previously announced client trial cessations which, as was noted in the Company's update of 24 May 2022, negatively affected its contracted orderbook for 2023. Reported Earnings • May 25
First half 2022 earnings released First half 2022 results: Revenue: (down 100% from 1H 2021). Net income: (down UK£842.0k from profit in 1H 2021). Profit margin: (down from 17% in 1H 2021). The decrease in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has only increased by 19% per year, which means it is significantly lagging earnings growth. Board Change • Apr 27
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Senior Independent Director Mark Warne was the last independent director to join the board, commencing their role in 2016. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Annuncio • Apr 25
IXICO plc Provides Revenue Guidance for the Six Months Ended March 31, 2022 IXICO plc provided revenue guidance for the six month ended March 31, 2022. Revenues expected to be £3.9 million for six months to 31 March 2022 (H1 2021: £4.9 million). Annuncio • Feb 15
IXICO plc Announces the Launch of IXIQ.Ai, A Novel Platform for Brain Segmentation Based on Convolutional Neural Networks IXICO plc announced the launch of IXIQ.Ai, a novel platform for brain segmentation based on convolutional neural networks. The platform has been developed and validated in collaboration with IXICO's academic and pharma partners and will be applied to clinical trials from March 2022. IXIQ.Ai provides IXICO's development engineers with an agile infrastructure to enable efficient and rapid deployment of analysis solutions ("plugins") for specific therapeutic indications or brain regions. IXIQ.Ai analysis is performed on a MRI scan to segment the brain structure relevant to a specific central nervous system ("CNS") indication. The platform is pre-trained on IXICO's database of clinical trial and natural history datasets across several CNS indications, which has benefited from machine learning improvements developed over the past 10 years. Based on the IXIQ.Ai platform infrastructure, plugins can be trained with a reduced number of highly curated datasets to obtain an optimised solution for a specific segmentation problem. IXIQ.Ai will include pre-developed and validated plugins for applications in Huntington's disease ("HD") and Alzheimer's Disease ("AD"). Scientific presentations with IXICO's academic and pharma partners have shown benefits of IXIQ.Ai over widely used brain imaging tools in three areas: Sensitivity to smaller treatment effects - every datapoint matters in efficacy analysis of imaging endpoints to increase the ability of detecting a treatment effect and, ultimately, to manage trial size, development time and costs; thereby improving overall efficiency in running clinical trials. The IXIQ.Ai platform increases the amount of usable data by 10%-20% on standard brain regions and can more than double it for challenging brain regions when compared to widely used tools, enabling the detection of proportionally smaller treatment effects without increasing trial size. Accuracy that enables patient-level decision making - a move towards precision medicine, as well as increasingly sophisticated drug candidates and administration modes in neuroscience, encourage applications of brain volumetry that drive individual patient decisions. Moving away from group-level statistics increases the requirements on accurate and reliable measurements at the patient level. Compared to widely used tools, IXIQ.Ai reduces volume error to manual expert segmentations by up to 80%, enabling more accurate patient-level decision-making. IXIQ.Ai provides measurements in real-time, enabling quick turnarounds in critical eligibility decision. Flexibility to adapt to customized trial needs - using an analysis solution tailored to specific patient populations or brain regions, enables greater accuracy compared to one-size-fits-all solutions. IXIQ.Ai can be flexibly adapted to a specific patient population by using only a small number of highly curated training cases, offering a customisable solution to address specific trial needs. The launch of IXIQ.Ai is scheduled to coincide with the 17th Annual Huntington's Disease Therapeutics Conference: A Forum for Drug Discovery & Development - 28th Feb. - 3rd March, Palm Springs, CA, where IXICO is presenting with pharma and academic partners on the application of the platform in HD imaging. Further validation of the AD workstream will be presented at the 16th International Conference on Alzheimer's & Parkinson's Diseases - 15th - 20th March, Barcelona. Annuncio • Feb 01
IXICO plc Appoints Lynne Hughes as Senior Therapeutic Advisor IXICO plc announced that it has appointed Dr. Lynne Hughes, an international neurology clinical trial research expert, to IXICO as a Senior Therapeutic Advisor to the Company. Dr. Hughes, who brings more than 35 years of experience in the global clinical research field, will use her deep neurology R&D expertise and knowledge of the global neurology landscape to advise and support IXICO's management in the development of the Company's therapeutic strategy. In particular, Dr. Hughes will focus on determining adjacent therapeutic areas into which IXICO can diversify into and expand the deployment of its proprietary neuroimaging CRO and AI data analytics services. Dr. Hughes most recently held the position of Vice President and Global Head, Medical and Therapeutic Strategy, Neurology at IQVIA. In a 23-year tenure at IQVIA, Dr. Hughes managed and was senior oversight on more than 450 trials including 125 trials relating to Alzheimer's disease (many of which she designed and managed from concept through to Phase III) and more than 75 trials in Parkinson's disease and 65 trials in Multiple Sclerosis. Dr. Hughes currently sits on multiple neurology therapeutic focused advisory boards, steering executive committees. She co-chairs one of the three global taskforces of the G20/World Economic Forum Alzheimer's Collaboration (DAVOS-DAC), the taskforce charged with expediting drug development in Alzheimer's disease, is a senior advisor to the Global Alzheimer's Platform foundation (GAP) and is a member of the NIA/NIH taskforce for recruitment into AD trials and the development of the US National Framework. In addition, Dr. Hughes has worked with various research organizations including the Gates Foundation, Alzheimer's Association, Alzheimer's Research UK, ADI and is a member of the G7 and G20 World Dementia Councils. Reported Earnings • Dec 08
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: EPS: UK£0.033 (up from UK£0.02 in FY 2020). Revenue: UK£9.19m (down 3.6% from FY 2020). Net income: UK£1.58m (up 65% from FY 2020). Profit margin: 17% (up from 10.0% in FY 2020). The increase in margin was driven by lower expenses. Revenue was in line with analyst estimates. Over the next year, revenue is expected to shrink by 5.6% compared to a 30% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 92% per year but the company’s share price has only increased by 37% per year, which means it is significantly lagging earnings growth. Reported Earnings • May 28
First half 2021 earnings released: EPS UK£0.018 (vs UK£0.01 in 1H 2020) The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: UK£4.91m (up 7.9% from 1H 2020). Net income: UK£842.0k (up 77% from 1H 2020). Profit margin: 17% (up from 10% in 1H 2020). Over the last 3 years on average, earnings per share has increased by 121% per year but the company’s share price has only increased by 40% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Apr 28
Investor sentiment improved over the past week After last week's 16% share price gain to UK£1.10, the stock trades at a trailing P/E ratio of 47.9x. Average forward P/E is 43x in the Life Sciences industry in Europe. Total returns to shareholders of 220% over the past three years. Annuncio • Apr 26
IXICO plc Provides Earnings Guidance for the Six Months Ended 31 March 2021 IXICO plc updated ahead of results for the six months ended 31 March 2021. Revenues expected to be £4.9 million for 6 months to 31 March 2021 (2019: £4.6 million), representing 8% growth. Annuncio • Apr 14
IXICO plc announced that it has received £1.2 million in funding from Merchant Capital Manager Limited IXICO plc (AIM:IXI) announced a private placement of 120,000,000 shares at an issue price of £0.01 per share for gross proceeds of £1,200,000 on April 12, 2021. The transaction will involve participation from CIP Merchant Capital Limited (AIM:CIP), a fund managed Merchant Capital Manager Limited for 1,784,500 shares for 3.72% stake and other investors. As part of the transaction, Wikus Van Schalkwyk represented Merchant Capital Manager Limited. Valuation Update With 7 Day Price Move • Mar 17
Investor sentiment improved over the past week After last week's 24% share price gain to UK£1.23, the stock trades at a forward P/E ratio of 71x. Average forward P/E is 45x in the Life Sciences industry in Europe. Total returns to shareholders of 232% over the past three years. Annuncio • Mar 15
IXICO plc Announces Collaboration with Microsoft IXICO plc announced a collaboration with Microsoft to develop its AI data analytics platform for the global pharmaceutical industry. Combining IXICO's portfolio of AI data analytics and scientific expertise in neurological diseases with Microsoft's cloud-based AI infrastructure, will provide a significant enabler for IXICO's delivery of clinical trial analytics solutions, at scale, to the pharmaceutical industry. As part of the collaboration, the two companies will work together to deliver IXICO's AI solutions into global clinical trials for neurological diseases such as Alzheimer's disease and Huntington's disease by enhancing IXICO's large-scale data processing capabilities. These capabilities will set the foundation for an expanded range of differentiated and proprietary AI driven services, assisting IXICO's customers in their efforts to address significant unmet medical needs. IXICO's remote access business model has supported significant growth in recent years and has proven to be an important differentiator in minimising disruption to clinical trials in the COVID-19 pandemic business environment. As the Company continues to scale in the highly regulated clinical trials environment, its cloud-based analytics platform is aimed at supporting decentralised clinical trial designs and the ability to collect and analyse greater volumes and types of therapeutic specific patient data, improving clinical insights available within neurological drug development. Annuncio • Mar 10
Ixico plc Announces That It Has Been Selected by A Current Mid-Sized Biopharmaceutical Client to Support the Company's Phase Ii Alzheimer's Disease Clinical Trial IXICO plc announces that it has been selected by a current mid-sized biopharmaceutical client to support the company's Phase II Alzheimer's disease clinical trial. Conducted across 125 sites in 10 countries over 5 years, the study will investigate an anti-Tau antibody treatment for individuals with prodromal and mild Alzheimer's disease (AD). For the study, IXICO will provide advanced neuroimaging solutions involving structural magnetic resonance imaging (MRI), volumetric MRI (vMRI), diffusion MRI (dMRI) and arterial spin labelling (ASL). AD affects approximately 50 million people worldwide with no available therapies to address the underlying disease pathology. Biopharmaceutical companies are responding to this challenge with innovations in clinical trials and treatment targets in their AD pipelines. These include increased diversification of drug candidates by investigating disease-modifying agents targeting pathways other than the historical focus area of amyloid. This new study, which follows on from the AD study award by Cyclerion Therapeutics Inc. announced on 2 March 2021, further demonstrates the important growing industry trend of target diversification in AD drug development. Whilst this contract does not change management's expectations of financial performance for the year, it adds to the Company's strong order book and further increases visibility of future revenues. Annuncio • Mar 04
IXICO plc Announces That It Has Been Selects by Cyclerion Therapeutics, Inc IXICO plc announced that it has been selected by Cyclerion Therapeutics Inc. to support the company's Phase IIa clinical trial to investigate CY6463 for treatment of individuals with Alzheimer's disease. For the study, IXICO will provide advanced neuroimaging solutions involving structural magnetic resonance imaging (MRI), diffusion MRI (dMRI), resting state functional MRI (rs-fMRI) and arterial spin labelling (ASL). Alzheimer's disease (AD) is a progressive degenerative disease affecting approximately 50 million people worldwide with devastating physical, emotional and financial impact to patients and families. With no available therapies to address the underlying disease pathology, new approaches are urgently needed, and biopharmaceutical companies are responding with innovations in clinical trials and treatment targets in their AD pipelines. This new study will be looking at the role of vascular pathology in AD, and more specifically, the potential of the NO-sGC-cGMP pathway as a target for new AD therapies. Whilst this contract does not change management's expectations of financial performance for the year, it adds to the Company's strong order book, further increases visibility of future revenues, and reflects an increasing diversification of the Company's client base. Is New 90 Day High Low • Jan 18
New 90-day low: €0.98 The company is down 4.0% from its price of €1.03 on 20 October 2020. The German market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €2.59 per share. Annuncio • Dec 26
IXICO Secures New Contract for £3.4 Million IXICO plc announced it has been awarded a £3.4 million contract to run over c.4.5 years by an existing client for a Spinocerebellar Ataxia type 3 (SCA3) trial. SCA3, also known as Machado-Joseph disease, is a rare, neurodegenerative condition resulting in movement disorders, rigidity, muscular atrophy and paralysis. Currently there is no treatment to slow down or reverse the progressive course of this terminal disease. For the study, IXICO will provide operational services and advanced AI neuroimaging solutions for volumetric, diffusion and functional magnetic resonance imaging as well as magnetic resonance spectroscopy and quantitative susceptibility mapping. Having singularly focused on neurological disorders since its inception, IXICO has a long and established track record of enabling biopharmaceutical sponsors to realise the full power of neuroimaging in CNS and rare disease clinical trials. Valuation Update With 7 Day Price Move • Dec 16
Investor sentiment deteriorated over the past week After last week's 15% share price decline to UK£1.02, the stock is trading at a trailing P/E ratio of 46x, down from the previous P/E ratio of 54.3x. This compares to an average P/E of 57x in the Life Sciences industry in Europe. Total returns to shareholders over the past three years are 257%. Reported Earnings • Dec 03
Full year 2020 earnings released: EPS UK£0.02 The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: UK£9.53m (up 26% from FY 2019). Net income: UK£952.0k (up 120% from FY 2019). Profit margin: 10.0% (up from 5.7% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 122% per year but the company’s share price has only increased by 64% per year, which means it is significantly lagging earnings growth. Analyst Estimate Surprise Post Earnings • Dec 03
Revenue beats expectations Revenue exceeded analyst estimates by 2.3%. Over the next year, revenue is forecast to grow 5.0%, compared to a 18% growth forecast for the Life Sciences industry in Germany. Annuncio • Dec 03
IXICO plc, Annual General Meeting, Jan 21, 2021 IXICO plc, Annual General Meeting, Jan 21, 2021, at 10:30 Coordinated Universal Time. Location: 4th Floor Griffin Court 15 Long Lane London United Kingdom Agenda: To approve re-election of directors. Annuncio • Nov 27
IXICO plc Announces £1.9 Million New Study Award IXICO plc announced that it has executed a contract to provide neuroimaging services that will support a phase Ib/II clinical trial for Huntington's disease. This will build on the Company's existing relationship with the sponsor with whom they contracted a prior safety and efficacy trial in 2019. By deploying innovative imaging biomarker solutions in early phase studies, IXICO enables biopharmaceutical sponsors to accelerate R&D decision making and maximize the value of their drug development pipelines. The new award reflects and reinforces the confidence customers place in IXICO as the trusted and leading neuroimaging partner for Huntington's disease clinical trials. This contract was included in management's expectations of performance for the current financial year but adds to the Company's strong order book. Valuation Update With 7 Day Price Move • Nov 24
Market bids up stock over the past week After last week's 16% share price gain to UK£1.31, the stock is trading at a trailing P/E ratio of 79.6x, up from the previous P/E ratio of 68.4x. This compares to an average P/E of 59x in the Life Sciences industry in Europe. Total returns to shareholders over the past three years are 301%. Is New 90 Day High Low • Nov 24
New 90-day high: €1.26 The company is up 35% from its price of €0.94 on 25 August 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. Valuation Update With 7 Day Price Move • Nov 20
Market bids up stock over the past week After last week's 15% share price gain to UK£1.25, the stock is trading at a trailing P/E ratio of 76.9x, up from the previous P/E ratio of 66.8x. This compares to an average P/E of 57x in the Life Sciences industry in Europe. Total returns to shareholders over the past three years are 281%. Annuncio • Nov 10
IXICO plc to Report Fiscal Year 2020 Results on Dec 02, 2020 IXICO plc announced that they will report fiscal year 2020 results on Dec 02, 2020 Valuation Update With 7 Day Price Move • Nov 09
Market bids up stock over the past week After last week's 15% share price gain to UK£1.26, the stock is trading at a trailing P/E ratio of 72.8x, up from the previous P/E ratio of 63.3x. This compares to an average P/E of 60x in the Life Sciences industry in Europe. Total returns to shareholders over the past three years are 257%. Is New 90 Day High Low • Oct 24
New 90-day high: €1.22 The company is up 59% from its price of €0.76 on 24 July 2020. The German market is down 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 13% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. Valuation Update With 7 Day Price Move • Oct 24
Market bids up stock over the past week After last week's 26% share price gain to UK£1.22, the stock is trading at a trailing P/E ratio of 71.1x, up from the previous P/E ratio of 56.7x. This compares to an average P/E of 61x in the Life Sciences industry in Europe. Total returns to shareholders over the past three years are 244%. Annuncio • Oct 16
IXICO plc and NYU Langone Health Signs Agreement IXICO plc announced that it has entered into an agreement with NYU Langone Health to support a trial to determine if the immunosuppressant drug Sirolimus approved by the FDA to prevent organ transplant rejection and for the treatment of a rare and progressive lung disease called lymphangioleiomiomatosis is also able to slow the progression of disease in people with Multiple System Atrophy (MSA). Working with NYU Langone clinicians and researchers, the trial will help develop biomarkers for MSA from magnetic resonance imaging (MRI). MSA is a condition of the central nervous system that causes gradual damage to nerve cells in the brain. The project involves application of IXICO's existing MSA analysis solutions on retrospectively collected MRI data from patients with MSA, dementia with Lewy Bodies, Parkinson's disease, and Progressive Supranuclear Palsy as well as the joint development of a novel solution to analyse susceptibility weighted imaging (SWI). Annuncio • Oct 04
IXICO plc Announces £2 Million Contract Extension Win - Huntington’s Disease IXICO plc has executed a c. £2 million contract to provide additional imaging services that will support a pivotal Huntington's disease (HD) study. This builds on the Company's existing contract to support 'top-20' pharma client's Phase III study in HD. This contract does not have significant impact on management's expectations of performance for the coming year, but will contribute to the Company's already strong order book for next year. Annuncio • Sep 24
Ixico plc Enters into 5 Year Collaboration with Friedreich's Ataxia Research Alliance IXICO plc announced that it has entered into a 5 year collaboration with the Friedreich's Ataxia Research Alliance (FARA), a non-profit organization dedicated to the pursuit of scientific research leading to treatments and a cure for Friedreich's Ataxia (FA). IXICO will become a member of the TRACK-FA Neuroimaging Consortium, working with clinicians and researchers to explore novel imaging markers in Friedreich's Ataxia. FA is a rare inherited, debilitating, life-limiting, degenerative neuro-muscular disorder, and although rare, it is the most common form of hereditary ataxia in the United States, affecting about 1 in every 50,000 people. FA causes progressive nervous system damage and movement problems and usually begins in childhood and leads to impaired muscle coordination (ataxia) that worsens over time, with the rate of progression varying from person to person. Generally, within 10 to 20 years after the appearance of the first symptoms the person is confined to a wheelchair. The TRACK-FA Neuroimaging Consortium is a representative group of stakeholders with interest in the design, conduct, support and participation in neuroimaging studies in FA, facilitating the exchange of data and other information with the goal of furthering the understanding of FA, identifying sensitive neuroimaging biomarkers and advancing the development of treatments for FA. IXICO will support the implementation of novel analysis algorithms, with the aim of providing a trial ready imaging solution for FA clinical trials. IXICO will be an industry member and stakeholder in the consortium, working alongside academic partners with expertise in neuroimaging and conducting clinical research in FA. These partners include Monash University (Australia), University of Minnesota (USA), Aachen University (Germany), University of Campinas (Brazil), University of Florida (USA), and Children's Hospital of Philadelphia (USA). Annuncio • Sep 22
Global Alzheimer's Platform Foundation Selects IXICO plc for Innovative Bio-Hermes Trial IXICO plc announced that is has been selected by the Global Alzheimer's Platform Foundation (GAP) to support GAP's planned Bio-Hermes trial. IXICO will apply its expertise to collect Positron Emission Tomography (PET) brain scans in qualifying imaging centres participating in Bio-Hermes and provide analysis of the scans. Bio-Hermes' core purpose is development of a bio-sample database to investigate biomarkers on a head-to-head basis in conjunction with medical history elements. The Bio-Hermes trial will include 1,000 volunteers over the age of 60 screened for Preclinical Alzheimer's Disease, Prodromal AD, or Mild Dementia AD. Observational biomarker studies consistently suggest that amyloid deposition and tau deposition in neurofibrillary tangles in the brain may be the sentinel events in Alzheimer's Disease pathology. In the Bio-Hermes trial, Avid Pharmaceuticals' Amyvid™ will be used as the radioactive diagnostic agent to estimate ß-amyloid neuritic plaque density.